Winter Storm Delays Cancer Treatment Across U.S.
Severe winter storms have affected multiple central U.S. states with power outages and water supply disruptions. State officials in Texas, Louisiana and Mississippi say restoring power to everyone could still take several days. Over the past week, problems with state infrastructure left millions of residents across Texas and Oklahoma without heat and potable water. Dr. Raja Flores, a thoracic surgeon at Mount Sinai Cancer Center in New York, says the weather has also affected cancer patients in his area. “With the storm, many services are not available,” Dr. Flores told The Mesothelioma Center at Asbestos.com. ...
Source: Asbestos and Mesothelioma News - February 22, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. “Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising drug for this d...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Study seeks to identify biological markers that predict mesothelioma response to treatment
(Baylor College of Medicine) The goal of this study is to develop a clinically relevant test that would enable physicians to determine whether a patient would be most likely or less likely to respond to a form of immunotherapy before the patient gets treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news
Research Reinforces Gene Mutation Links to Mesothelioma
More than ever, Dr. Michele Carbone at the University of Hawaii Cancer Center believes early testing for genetic mutations can lead to fewer cases of malignant mesothelioma and a longer survival time for many who do contract the disease. Lives can be saved. Years can be added. “It could change the way we treat these patients,” Carbone told The Mesothelioma Center at Asbestos.com. “And, in some cases, it could prevent the cancer entirely.” Carbone is director of thoracic oncology at University of Hawaii and a world leader in identifying the role of genetics in the development of mesothelioma cancer. He led a team of...
Source: Asbestos and Mesothelioma News - February 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Mesothelioma Still Prevalent in Canada Following Asbestos Ban
More than two years after implementing a much-celebrated ban of asbestos, Canadians have come to realize the real fight has only just begun. Malignant mesothelioma cancer isn’t going away any time soon. Asbestos exposure may be the only confirmed cause of mesothelioma, but the nationwide ban of the toxic mineral is not predicted to slow the rise in cases for decades. It is expected to change the face of those being diagnosed. “It’s going to be awhile before we see any major decline in numbers,” Dr. Paul Demers, director of the Occupational Cancer Research Centre at Ontario Health, told The Mesothelioma Center at As...
Source: Asbestos and Mesothelioma News - February 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Opdivo Study Offers Hope to Relapsed Mesothelioma Patients
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival. Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug already being used successfully with non-small cell lung cancer. It is the first drug to show a significant survival advantage for relapsed mesothelioma in a phase III clinical trial, according to principal investigator Dr. Dean Fennell, medical oncologist at the University of Leicester in England. “This is very encouraging news,” Fennell told Th...
Source: Asbestos and Mesothelioma News - February 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Researchers: Mesothelioma Trials Need More Inclusive Criteria
Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney, Australia. The study demonstrated a significant difference between those carefully selected for clinical trials and real-world patients with pleural mesothelioma. “A broader patient population more resembling real life would be able to access the novel treatment early,” Dr. Steven Kao, medical oncologist at Chris O’Brien Lifehouse hospital and one of the study authors, told The Mesothelioma Center at Asbestos.com. “And when the tr...
Source: Asbestos and Mesothelioma News - February 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Nivolumab Improves Survival in Relapsed Mesothelioma Nivolumab Improves Survival in Relapsed Mesothelioma
In the first placebo-controlled phase 3 trial in relapsed mesothelioma, immunotherapy with nivolumab showed a significant improvement in survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New weapon in battle with cancer caused by asbestos
Results from a trial show the drug nivolumab can help keep the aggressive disease mesothelioma at bay for months or even years. (Source: the Mail online | Health)
Source: the Mail online | Health - January 30, 2021 Category: Consumer Health News Source Type: news
Nivolumab effective treatment for malignant mesothelioma
(International Association for the Study of Lung Cancer) Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2021 Category: Cancer & Oncology Source Type: news
EPA ’s Asbestos Risk Evaluation Faces Litigation
The Asbestos Disease Awareness Organization continued its challenge of the U.S. Environmental Protection Agency, filing a petition for review Jan. 26 in the U.S. Court of Appeals for the Ninth Circuit and an intent to sue notice under the Toxic Substances Control Act. ADAO, the leading nonprofit aimed at preventing asbestos exposure and raising awareness about mesothelioma, was joined by five public health groups and six doctors and scientists in its latest filings. The petition for review is aimed at the EPA’s Final Risk Evaluation for Asbestos from earlier this month that was roundly criticized for underestimating the ...
Source: Asbestos and Mesothelioma News - January 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Study: Mesothelioma Survival Rates Rise with SMART Protocol
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a larger clinical trial at the Princess Margaret Cancer Centre in Toronto. Lancet Oncology recently published results of the study, named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. The SMART study involved 96 patients with pleural mesothelioma who were treated in Toronto from 2008 to 2019. All received the intensity-modulated radiotherapy before extrapleural pneumonectomy surgery, an unconventional treatment regimen. Among the...
Source: Asbestos and Mesothelioma News - January 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Thoracic Chemotherapy May Advance Mesothelioma Treatment
Thoracic surgeon Dr. Marcello Migliore is convinced that adding hyperthermic intrathoracic chemotherapy to aggressive surgery can extend survival significantly for patients with pleural mesothelioma cancer. He wants others to know that, too. This seldom-used, controversial procedure, also known as HITHOC, involves circulating a heated, high-concentration chemotherapy solution throughout the chest cavity for 60 minutes immediately following aggressive mesothelioma surgery. The idea is to kill any microscopic tumor cells that evaded the surgeon, hopefully slowing a potential cancer recurrence. Unlike HIPEC, a similar procedu...
Source: Asbestos and Mesothelioma News - January 19, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Statins May Give Boost to Mesothelioma Immunotherapy Drugs
This study, which included both patients with pleural mesothelioma and with advanced non-small cell lung cancer, found a potential synergy with the immunotherapy drugs. Opdivo and Keytruda, generically called nivolumab and pembrolizumab, respectively, are known as PD-1 inhibitors, drugs that restrict a protein from stopping immune response to cancer cells. “Statins may lead to prolonged antigen retention on cell membrane and strengthen antigen presentation to T cells, thus suggesting a potential synergy with PD-1 inhibitors,” the authors wrote. “The anti-tumor effect of statins might be attributed to an indirect immu...
Source: Asbestos and Mesothelioma News - January 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
EPA Evaluation Finds Asbestos Still An Unreasonable Risk
The U.S. Environmental Protection Agency released Part 1 of its Final Risk Evaluation for Asbestos, reaffirming preliminary findings from March that were roundly criticized for underestimating the dangers of exposure to this toxic mineral. Six ongoing use categories of asbestos were evaluated by the EPA, which found 16 conditions of use that presented unreasonable risk to human health through either occupational exposures or consumer uses. Part 1 of the evaluation, released in late December 2020, involved the chrysotile type of asbestos. Chrysotile is the only type of asbestos being imported, processed or distributed for u...
Source: Asbestos and Mesothelioma News - January 6, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news